Olfactive Biosolutions to replace pharmaceuticals with natural food molecules treating diabetes and obesity

Olfactive Biosolutions, which is adapting food molecules to treat chronic diseases, has secured a third US patent covering a novel method for stimulating the production of GLP-1 and GIP (gastric inhibitory polypeptide), hormones crucial for regulating blood sugar. Poised as an alternative therapy for diabetes and obesity, it is based on natural food molecules that activate smell and taste receptors found across the body.

With its proprietary formulations based on “cheap and plentiful” food molecules, the company intends to replace conventional weight management pharmaceuticals globally. Unlike some medicines, they come without side effects and can be consumed on a long-term basis.

Food and beverage manufacturers will soon be able to add these molecules to their consumer products, bringing benefits “consistent with current prescription-only pharmaceuticals without requiring any changes in consumer behavior or routines and without side effects.”

Stimulating receptors across the body

Olfactory and taste receptors are not just in the nose and tongue, but elsewhere in the body — the lungs, vasculature, gut, testes, heart and kidneys.

These ectopic receptors influence GLP-1 and GIP secretion, serotonin and dopamine secretion, blood pressure, muscle regeneration, bone remodeling, bronchodilation, kidney function and many other physiological pathways.

Olfactive Biosolutions’ flagship line of products, Pivit, stimulate these olfactory and taste receptors in the gut and across the body, delivering similar physiological effects of active pharmaceutical ingredients “at a fraction of the cost and without side effects.”

The company plans to release its new Pivit Weight Management product direct-to-consumers early this year. This supplement works by stimulating smell-related receptors in the gut. This triggers the body to naturally release GLP-1 and GIP, hormones that promote weight loss by regulating blood sugar.

“We are excited to have been granted this additional patent [US 12,171,727 B1] for GLP-1 Weight Management, another important formulation in our line of Pivit products. We now have five granted patents for the treatment of diabetes, obesity, high blood sugar and hypertension,” says Nils Lommerin, president and CEO of Olfactive Biosolutions.

Olfactive Biosolutions employs several prominent biotechnology advisors from academia and the corporate world; Lommerin is a former president, CEO and director of Del Monte Foods.

In other breakthrough food science, Tate & Lyle recently partnered with botanical biotech specialist BioHarvest Sciences to develop “next-generation sustainable and economic sweeteners” synthesized from patentable molecules. This is done using BioHarvest’s Botanical Synthesis platform, which grows plant cells that “mirror and magnify” phytonutrients in specific plants.